During the past decade, Accelerated Enrollment Solutions conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 2 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Accelerated Enrollment Solutions" are "Alzheimer's Disease" (3 trials), "Alzheimer Disease" (1 trials) and "Mild to Moderate Alzheimer's Disease" (1 trials). Many other conditions were trialed in "Accelerated Enrollment Solutions" in a lesser frequency.

Most popular intervention types in "Accelerated Enrollment Solutions" are "Drug" (5 trials). Other intervention types were less common.

The name of intervention was led by "Gantenerumab" (3 trials), "Placebo" (3 trials), "AR1001" (1 trials) and "Aducanumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Accelerated Enrollment Solutions" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Accelerated Enrollment Solutions". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Accelerated Enrollment Solutions, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Accelerated Enrollment Solutions, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".